Overview

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Status:
Completed

Trial end date:
2018-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to estimate the overall response rate of subjects with relapsed or refractory Adult T-cell Leukemia-Lymphoma (ATL).

Phase:

Phase 2

Details

Lead Sponsor:

Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin, Inc.

Treatments:

Aminopterin
Antibodies, Monoclonal
BB 1101
Cisplatin
Cytarabine
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Gemcitabine
Mogamulizumab
Oxaliplatin